Document is current
Any future updates will be listed below
-
Authors
Shishido, Stephanie N
Hart, Olivia
Jeong, Sujin
Moriarty, Aidan
Heeke, Darren
Rossi, John
Bot, Adrian
Kuhn, Peter https://orcid.org/0000-0003-2629-4505
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02614066 at ClinicalTrials.govDocuments that mention this clinical trial
Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
https://doi.org/10.1200/jco.2023.41.16_suppl.7023
Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy
https://doi.org/10.1136/jitc-2023-007329
Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
https://doi.org/10.1200/jco.2024.42.16_suppl.6531
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
https://doi.org/10.1136/jitc-2023-007118
-
Funding
Funding for this research was provided by:
Kite Pharma, Inc (N/A)
- License Information
